Drug labels would have to name allergen-derived ingredients under HR 3821

What does this do?

HR 3821 would require prescription and over-the-counter drug labels to clearly identify any ingredients derived from major food allergens or gluten-containing grains, including wheat, barley, and rye. A drug would be considered mislabeled under federal law if it contains those ingredients without disclosing them. Manufacturers would have up to two years after enactment to update their labels, or sooner if the Department of Health and Human Services sets an earlier deadline.

Who does it affect?

People with food allergies, celiac disease, or gluten sensitivities who take medications regularly are the primary population affected. Pharmaceutical companies would also be affected, as they would need to review and update product labeling across their drug lines.

Why does it matter?

Current federal allergen disclosure rules apply to food products but not to medicines, meaning drug fillers, coatings, and binders derived from allergens can appear on labels without clear identification. Patients who need this information currently must conduct their own research or contact manufacturers directly rather than finding it on the packaging.

Where does it stand?